Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that 9 additional patients have entered its Expanded Access Program (EAP) with drug candidate CS1 in rare disease pulmonary arterial hypertension (PAH). In total, the EAP now includes 10 patients with the possibility of more patients being included in the coming months. The additional data collected on the patients in the EAP will strengthen the long-term safety and efficacy documentation of CS1 and
